Ziyu Zhu

Ziyu Zhu

Auto-generated profile, based on publicly available information

Ziyu Zhu

Affiliated Mental Health Center & Hangzhou Seventh People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2020 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
ZYZiyi Yang
Ziyi Yang
MWMin Wang
Min Wang
ZZZiyu Zhu
Ziyu Zhu
YLYi Liu
Yi Liu
Objective: To summarize currently available evidence on maternal, fetal, and neonatal outcomes of pregnant women infected with Coronavirus Disease 2019 (COVID-19). Material and methods: PubMed, Google Scholar, CNKI, Wanfang Data, VIP, and CBMdisc were searched for studies reporting maternal, fetal, and neonatal outcomes of women infected with COVID-19 published from 1 January 2020 to 26 March 2020. The protocol was registered with the Open Science Framework (DOI: 10.17605/OSF.IO/34ZAV). Results: In total, 18 studies comprising 114 pregnant women were included in the review. Fever (87.5%) and cough (53.8%) were the most commonly reported symptoms, followed by fatigue (22.5%), diarrhea (8.8%), dyspnea (11.3%), sore throat (7.5%), and myalgia (16.3%). The majority of patients (91%) had cesarean delivery due to various indications. In terms of fetal and neonatal outcomes, stillbirth (1.2%), neonatal death (1.2%), preterm birth (21.3%), low birth weight (<2500 g, 5.3%), fetal distress (10.7%), and neonatal asphyxia (1.2%) were reported. There are reports of neonatal infection, but no direct evidence of intrauterine vertical transmission has been found. Conclusions: The clinical characteristics of pregnant women with COVID-19 are similar to those of non-pregnant adults. Fetal and neonatal outcomes appear good in most cases, but available data only include pregnant women infected in their third trimesters. Further studies are needed to ascertain long-term outcomes and potential intrauterine vertical transmission.

24 November 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
MDMengran Du
Mengran Du
JFJiayuanyuan Fu
Jiayuanyuan Fu
JZJie Zhang
Jie Zhang
ZZZiyu Zhu
Ziyu Zhu
XHXuekang Huang
Xuekang Huang
YCYuan Cheng
Yuan Cheng
Background: Depression is a common but often overlooked consequence in individuals with post‐traumatic brain injury (TBI). Circular RNAs (circRNAs) play essential roles in the nervous system, yet their involvement in the cell death mechanism known as cuproptosis and in TBI‐related depression remains unclear.Objectives: This study aimed to investigate the role of circRNA, specifically circSpna2, in the regulation of cuproptosis and its association with depression in TBI patients.Methods: RNA sequencing (RNA‐Seq) was used to assess the differential expression of circRNAs. Depression was evaluated using subjective and objective rating scales, and circSpna2 expression levels in plasma were measured. Further functional experiments were conducted in TBI mouse models, including knockdown and overexpression of circSpna2, to explore its impact on the Keap1‐Nrf2‐Atp7b pathway and cuproptosis.Results: TBI patients exhibited decreased levels of circSpna2, which correlated with depression (p < 0.0001). Knocking down circSpna2 in TBI mice aggravated depression‐like symptoms (p < 0.0001). Mechanistically, circSpna2 was found to bind ubiquitin ligase Keap1, modulating the Nrf2‐Atp7b signaling pathway and influencing cuproptosis (docking score: −331.88). Overexpression of circSpna2 alleviated cuproptosis after TBI through the Keap1/Nrf2/Atp7b axis.Conclusions: CircSpna2 plays a regulatory role in cuproptosis and may serve as a novel biomarker and therapeutic target for depression following TBI. Enhancing circSpna2 expression could mitigate depression after TBI by modulating the Keap1/Nrf2/Atp7b pathway.Key points: This study explores the role of circSpna2 in depression following traumatic brain injury (TBI). It was found that circSpna2 is significantly downregulated in TBI patients, and its expression levels correlate with depressive symptoms. In TBI mouse models, overexpression of circSpna2 alleviated depression‐like behaviours, while its knockdown exacerbated these symptoms, suggesting its potential as both a biomarker and a therapeutic target for post‐TBI depression. Mechanistically, circSpna2 regulates the Nrf2‐Atp7b signalling pathway by binding to the DGR domain of Keap1, which prevents Nrf2 ubiquitination and enhances Nrf2 activity. This in turn promotes the transcription of Atp7b, a copper transport protein, helping to maintain copper homeostasis and mitigate copper‐induced oxidative stress, a key protein of cell death (cuproptosis). The overexpression of circSpna2 also improved mitochondrial function and synaptic integrity, which are typically impaired by copper dysregulation. These findings highlight the therapeutic potential of circSpna2 in managing TBI‐related depression through the regulation of oxidative stress and copper homeostasis.

31 October 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
ZZZiyu Zhu
Ziyu Zhu
ZYZiyi Yang
Ziyi Yang
CWChunyi Wang
Chunyi Wang
HLHandeng Liu
Handeng Liu
Background. The morbidity of eczema has increased in the recent years, and the methods to prevent or ameliorate its effects are becoming more important. To this end, this research was conducted to determine the effectiveness of vitamin supplements in eczema therapy. Method. Embase, PubMed, and Cochrane Central Register of Clinical Trials were searched. Only randomized controlled trials were included, and we included all quantified eligible data where the SCORing Atopic Dermatitis (SCORAD) Index or Eczema Area and Severity Index (EASI) scores were applied to assess the severity of eczema. Results. Ten studies fulfilled the inclusion criteria, and eight of them were included for quantitative analysis (total: 456 patients). Compared to the controls, the SCORAD index or EASI decreased in the vitamin supplement group (mean difference −5.96, 95% CI: −7.69 to −4.23 for vitamin D3; mean difference −5.72, 95% CI: −11.41 to −0.03 for vitamin E; and mean difference −3.19, 95% CI: −4.27 to −2.10 for vitamin B12). Conclusion. This study suggests that vitamin supplements could be important therapeutics to help manage eczema patients.

1 August 2026 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
YXYilin Xiong
Yilin Xiong
ZZZiyu Zhu
Ziyu Zhu
CSCaijie Shen
Caijie Shen
WDWei Deng
Wei Deng
YCYuqi Cheng
Yuqi Cheng
Major depressive disorder (MDD) is increasingly recognized as a systemic disorder involving dysregulation of the heart-brain axis (HBA). Mounting evidence links impaired HBA signaling to the pathogenesis of major depressive disorder. Emerging data indicate that neuromodulation-mediated autonomic alterations correlate with depressive symptom remission. Although neuromodulatory therapies are widely deployed clinically, HBA-based biomarkers remain experimental, and no consistent physiological predictors of treatment response have been established to date. This review summarizes HBA dysfunction in depression across neural, biochemical, and mechanical pathways, integrating evidence from preclinical and clinical studies. We critically evaluate recent advances in leveraging these pathways to optimize neuromodulation strategies. Emerging evidence suggests that certain neuromodulation approaches—including transcranial magnetic stimulation (TMS), transcranial electrical stimulation (TES), vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), and deep brain stimulation (DBS)—may modulate heart-brain axis function. It has been hypothesized that such modulation could represent a physiological pathway contributing to mood improvement, providing a rationale for a heart-oriented framework in neuromodulation research. However, the clinical utility of this framework and its underlying biomarkers remain to be established through rigorous long-term investigations. By bridging the conventional conceptual divide between psychiatric and cardiovascular diseases, this review offers a systems-level perspective on neuromodulation efficacy and highlights the potential of HBA-related biomarkers for assessing pathological states and guiding treatment strategies in depression and other psychosomatic conditions.

7 August 2024 in JMIR Medical Informatics
Verified
Journal Article
Open access
ZZZiyu Zhu
Ziyu Zhu
LLLan Liu
Lan Liu
MDMin Du
Min Du
MYMao Ye
Mao Ye
XXXiming Xu
Ximing Xu
YXYING XU
YING XU
Background: Recently, the growing demand for pediatric sedation services outside the operating room has imposed a heavy burden on pediatric centers in China. There is an urgent need to develop a novel system for improved sedation services. Objective: This study aimed to develop and implement a computerized system, the Pediatric Sedation Assessment and Management System (PSAMS), to streamline pediatric sedation services at a major children’s hospital in Southwest China. Methods: PSAMS was designed to reflect the actual workflow of pediatric sedation. It consists of 3 main components: server-hosted software; client applications on tablets and computers; and specialized devices like gun-type scanners, desktop label printers, and pulse oximeters. With the participation of a multidisciplinary team, PSAMS was developed and refined during its application in the sedation process. This study analyzed data from the first 2 years after the system’s deployment. Implementation (Results): From January 2020 to December 2021, a total of 127,325 sedations were performed on 85,281 patients using the PSAMS database. Besides basic variables imported from Hospital Information Systems (HIS), the PSAMS database currently contains 33 additional variables that capture comprehensive information from presedation assessment to postprocedural recovery. The recorded data from PSAMS indicates a one-time sedation success rate of 97.1% (50,752/52,282) in 2020 and 97.5% (73,184/75,043) in 2021. The observed adverse events rate was 3.5% (95% CI 3.4%‐3.7%) in 2020 and 2.8% (95% CI 2.7%-2.9%) in 2021. Conclusions: PSAMS streamlined the entire sedation workflow, reduced the burden of data collection, and laid a foundation for future cooperation of multiple pediatric health care centers.

17 April 2026 in Medicine
Verified
Journal Article
Open access
LLLian Liu
Lian Liu
ZZZiyu Zhu
Ziyu Zhu
MDMengran Du
Mengran Du
XLXin Liu
Xin Liu
QTQiuhao Tan
Qiuhao Tan
ZLZB Liao
ZB Liao
Depression and post-traumatic stress disorder (PTSD) are common psychiatric disorders following physical trauma. However, genetic evidence between these disorders is lacking. DNA methylation (DNAm) is implicated in the response to traumatic events and has been proposed as a promising therapeutic target. This study aimed to investigate the causal evidence of injury-associated DNAm and the subsequent onset of depression or PTSD. We performed co-methylation analysis of the whole-genome bisulfite sequencing (WGBS) data from physical trauma patients who developed subsequent depression or PTSD. DNA methylation quantitative trait loci (mQTL) from the GoDMC database, expression quantitative trait loci (eQTL) from the eQTLGen consortium (phase Ⅰ), and genome-wide association (GWAS) summary statistics from the FinnGen consortium were used for causal inference using the mendelian randomization (MR) framework. Our results showed significant causal genetic evidence for injury-associated DNAm changes at cg24526596 (DLGAP2), cg00157656 (ERICH1), cg12317217 (PCDHA2), and cg12661624 (PTPRN2) on depression onset. However, no strong causal evidence was found for injury-associated DNAm and PTSD. The present study provided genetic evidence supporting the causal role of DNAm in the onset of depression or PTSD after injury and identified DLGAP2, ERICH1, PCDHA2, and PTPRN2 as the candidate genes worthy of further exploratory investigation.